PTPN11 and juvenile myelomonocytic leukemia: In models of Noonan syndrome and JMML, SFX-01 normalises Shp2 activity, reduces myeloid cells number, inhibits stem cell proliferation and induces cell-cycle arrest, demonstrating the drug’s therapeutic potential.